“ "The company invests a lot into education with doctors, using them as a middle man between the company and the patients." ”
In Conversation
“ "When looking at pharmaceuticals and the health sector, Serbia suffers from similar problems to the rest of Eastern Europe." ”
Interview: Darius Sinkevičius – Chairman of the Board, Lithuanian Association of Generic Pharmaceuticals Manufacturers (VGA)
“ "It bears mentioning that Lithuania has good level of inclusion of new chemical entities into the reimbursement list and, indeed, around 50 new products have been… ”
“ "As the premier research based company in the world, we are strongly committed to remain at the forefront of the Polish innovative landscape." ”
“ "Rare diseases affect – in total - a large population. However, individual rare diseases are very heterogeneous and people affected by these as well as their… ”
“ Looking at our productivity in 2017 alone, which includes three new therapy approvals, it is clear that the model we established makes good sense ”
“ "Serbia really has a huge potential especially in the innovation and technology sectors, but current developments in these areas are still modest." ”
Interview: Alexander Biach – Chairman, Hauptverband (Main Association of Austrian Social Security Institutions)
“ "We have the highest coverage of citizens of any country in Europe, which has been highlighted by studies by the OECD and the London School of… ”
“ "Serbia has such agreements and tax laws with the EU allowing us to import and export goods without paying customs." ”
Interview: Gintautas Barcys – Director, State Medicines Control Agency (SMCA), Ministry of Health, Lithuania
“ "Expanding on other interesting trends, it is a reality that more and more companies are willing to launch their products to the Baltic region and Lithuania,… ”
“ "The purpose behind the creation of Biognosys was to better understand the mode of action of various drugs and biological processes by understanding the changes in… ”
“ "Every year the number of innovative products entering the market is improving, despite our government placing pricing pressures on companies to lower the costs of treatment." ”